Zacks Investment Research upgraded Alimera Sciences Inc (NASDAQ:ALIM) to Hold in a statement released earlier today.
- Updated: November 29, 2016
Having a price of $1.12, Alimera Sciences Inc (NASDAQ:ALIM) traded -1.77% lower on the day. With the last close down -24.40% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the same period. Alimera Sciences Inc has recorded a 50-day average of $1.26 and a two hundred day average of $1.47. Volume of trade was up over the average, with 313,572 shares of ALIM changing hands over the typical 259,328
Zacks Investment Research has upgraded Alimera Sciences Inc (NASDAQ:ALIM) to Hold in a statement released on 11/29/2016.
With a total market value of $0, Alimera Sciences Inc has with a one year low of $1.01 and a one year high of $5.15 .
A total of 2 analysts have released a report on Alimera Sciences Inc. zero analysts rating the company a strong buy, three analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $7.50.
More About Alimera Sciences Inc (NASDAQ:ALIM)
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.